Arcutis Biotherapeutics has announced promising results from its Phase 3 INTEGUMENT-OLE study concerning the investigational ZORYVE cream for treating atopic dermatitis (AD). The long-term study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback